(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

Coughing up phlegm feels gross, especially if you’re already dealing with other unpleasant symptoms from a cold or other ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

Follow all of Sunday's NCAA Tournament second round games with USA TODAY Sports' live updates. Iowa State took a 31-30 lead into halftime against No. 7 seed Kentucky in the second round of the NCAA ...

The Switch 2 is faster, sharper, and packed with more features than its predecessor. It also costs more, but that price might climb even higher if recent rumors are true. Here's how it compares with ...

All three phones in Samsung's Galaxy S26 lineup look equally compelling—making your buying decision tougher than ever. Using data and observations from my reviews, I break down what sets each model ...